Performance of MRgFUS in pediatric patients has not been well characterized. Retrospective review of 21 MRgFUS treatments in 9 patients below the age of 18 shows significant reduction in viable tumor volume in a variety of indications including desmoid tumors, vascular malformations, and osteoid osteoma. MRgFUS is an effective ablative therapy in children that warrants further investigation.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords